Biotest AG | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
500,800.00
582,000.00
534,600.00
408,000.00
378,100.00
400,300
Cost of Goods Sold (COGS) incl. D&A
302,800.00
366,500.00
333,800.00
246,400.00
262,100.00
272,900
Gross Income
198,000.00
215,500.00
200,800.00
161,600.00
116,000.00
127,400
SG&A Expense
143,900.00
164,300.00
160,200.00
125,400.00
145,500.00
124,300
EBIT
47,600.00
47,900.00
-
-
32,200.00
1,700
Unusual Expense
2,400.00
1,300.00
2,000.00
1,000.00
17,800.00
4,500
Non Operating Income/Expense
5,000.00
6,100.00
2,400.00
700.00
4,600.00
3,200
Interest Expense
3,700.00
9,700.00
7,600.00
11,100.00
7,700.00
9,500
Pretax Income
46,800.00
46,900.00
32,800.00
22,600.00
26,100.00
5,800
Income Tax
15,800.00
27,700.00
7,800.00
17,900.00
9,600.00
6,900
Equity in Affiliates
1,000.00
-
2,000.00
1,400.00
100.00
200
Consolidated Net Income
32,000.00
19,200.00
27,000.00
6,100.00
16,400.00
12,900
Net Income
32,000.00
19,200.00
27,000.00
6,000.00
16,400.00
12,900
Net Income After Extraordinaries
32,000.00
19,200.00
136,500.00
57,800.00
29,300.00
207,500
Net Income Available to Common
32,000.00
19,200.00
82,500.00
45,800.00
3,500.00
180,900
EPS (Basic)
0.85
0.49
2.08
1.16
0.09
4.57
Basic Shares Outstanding
37,396.60
39,571.50
39,571.50
39,571.50
39,571.50
39,571.50
EPS (Diluted)
0.86
0.49
2.08
1.16
0.09
4.57
Diluted Shares Outstanding
37,396.60
39,571.50
39,571.50
39,571.50
39,571.50
39,571.50
EBITDA
79,400.00
80,400.00
60,700.00
54,000.00
9,900.00
26,300
Other Operating Expense
6,500.00
3,300.00
1,900.00
2,100.00
2,700.00
1,400
Non-Operating Interest Income
300.00
1,300.00
1,300.00
1,300.00
600.00
3,300
Minority Interest Expense
-
-
-
100.00
-
-

About Biotest

View Profile
Address
Landsteinerstrasse 5
Dreieich Hessen 63303
Germany
Employees -
Website http://www.biotest.de
Updated 07/08/2019
Biotest AG engages in the development and distribution of biological and biotechnological pharmaceutical products. It focuses in the field of clinical immunology, haematology, and intensive care medicine. The company operates through the following segment: Therapy, Plasma & Services, and Other.